

# Our approach to access to medicines

## Hikma Pharmaceuticals

### Contents

<a href="#">Introduction</a> .....	2
<a href="#">The role of generic pharmaceuticals in driving access</a> .....	2
<a href="#">Our approach to access to medicines</a> .....	3
<a href="#">How we govern access to medicines</a> .....	4
<a href="#">Addressing access challenges across regions</a> .....	5
<a href="#">North America</a> .....	5
<a href="#">MENA</a> .....	5
<a href="#">Europe</a> .....	5
<a href="#">Pursuing a holistic approach to meeting patient needs</a> .....	6
<a href="#">Expanding biosimilar treatment options in MENA</a> .....	6
<a href="#">Supporting HCPs to improve patient treatment and outcomes</a> .....	6
<a href="#">Our ambitions going forward</a> .....	6

## Introduction

Hikma is a growing global healthcare company dedicated to improving people's lives by providing broad access to hundreds of affordable high-quality medicines in communities across North America, the Middle East, North Africa and Europe. This is embodied by our corporate purpose: putting better health within reach, every day.

Guided by this purpose, we continually focus our resources and efforts on increasing access to medicine. We do this by developing and launching more products at competitive prices across our markets, expanding availability of our existing product portfolio through new country entry, investing in our global manufacturing capabilities, promoting disease awareness and educational initiatives, applying face-to-face customer engagement and by donating millions of doses of essential medicines to people and communities in need.

As the world's population continues to grow and age, the prevalence of chronic, non-communicable diseases also continues to grow, driving demand for better, more accessible healthcare, and we are committed and well-positioned to respond to this growing demand. Our primary activity is producing and selling high-quality medicines. We also work with stakeholders across our value chain to improve the healthcare ecosystems in the countries in which we operate, support patient needs, impact policy and national healthcare systems, respond to crises and urgent needs, and better inform healthcare professionals (HCPs) and patients.

## The role of generic pharmaceuticals in driving access

Generic pharmaceutical companies play a pivotal role in enhancing global access to medicines by providing high-quality, cost-effective alternatives to brand-name drugs. The manufacture and availability of generic medicines contributes to making essential medications more affordable and consistently available. This facilitates broader access to treatments, alleviates global healthcare disparities and supports the effective management of increasingly prevalent chronic conditions.

## Our approach to access to medicines

- **Manufacturing quality medicines locally across three continents:** We operate 29 manufacturing facilities across 11 countries. We are committed to prioritising the availability and accessibility of more affordable, high-quality generic medicines by leveraging our local presence to ensure long-term security of supply and reliable access for patients.
- **Investing in Research and Development (R&D) and Business Development (BD) to bring more products to market:** We invest c.6-7% of our revenue each year into our R&D programme to ensure we are able to grow our portfolio and offer our customers and their patients a broad range of essential medicines. Through R&D and BD we can launch products that may not have previously been available or affordable to the patients, or that can help to address shortage situations.
- **Engaging with HCPs and patients to improve patient journey:** We are committed to working with HCPs, clinics and directly with patients to improve the overall patient journey. We pursue a holistic approach to improving the patient journey. Examples of this include the development of patient support programmes as well as awareness and education programmes for patients and HCPs. We continue to leverage digital tools to strengthen patient awareness, and capacity-building programmes that enable better patient outcomes.
- **Working alongside industry peers and associations:** We work with industry partners to sell in-licensed patented products in our markets, as well as offer contract manufacturing services. We also form collaborations with sector-specific/industry-driven associations to support policies that encourage the availability of generic medicines to patients.
- **Engaging with governments and policymakers:** We continuously engage with policymakers to better align our activities with national health priorities. We also engage and coordinate with national governments during crisis situations to support access to medicines or APIs.
- **Responding to crises and urgent social needs:** We are committed to leveraging our Medicine Donations Programme to respond to crisis situations, support patients with chronic conditions, and provide relief to marginalised population segments with donated medicines. We have streamlined processes with global NGOs to offer donations of medicines and medical equipment

## How we govern access to medicines



## Addressing access challenges across regions

How we address health equity varies across our markets and considers the unique priority health areas, barriers, challenges and opportunities that impact healthcare disparities across geographies and populations.

### North America

We are a top three supplier of generic injectable medicines in the US, and one of the larger suppliers of non-injectables medicines. With our US-based manufacturing facilities and broad product portfolio, supported by our global manufacturing base, we are uniquely positioned to not only supply a wide range of products, but to respond quickly to shortage situations and work with our customers to help address patient needs. We have a growing presence in Canada, where we are also addressing shortage situations. In addition, we remain focused on promoting community health, and work with public and private institutions to address the opioid epidemic through access and awareness of our injectable, oral and nasal solutions to opioid overdose.

### MENA

We are committed to prioritising the treatment of increasingly prevalent chronic diseases in our MENA markets, including diabetes, respiratory illness, cardiovascular and cancer. Our local presence and expertise across these markets ensures security of supply while our customer and government relationships allow us to prioritise products most in need. We continue to collaborate with policymakers, HCPs, payers and patients to increase education and strengthen the resilience of healthcare ecosystems that address the barriers to access of patients.

Leveraging and expanding local manufacturing capabilities across the region enables a more secure and stable supply for essential and chronic treatments and is integral to our overall strategy. In several of our operating countries in MENA, we leverage our presence as the only local manufacturer of oral oncology products to improve the reliability and affordability of cancer-treating medicines. The construction of injectable manufacturing facilities in Algeria, Morocco and Saudi Arabia as well as facility expansions regionally will all similarly facilitate access to existing and new medicines and decrease exposure to supply chain risks.

### Europe

We have an established and growing presence in Europe, where we supply injectable products across the large EU5 markets, while continuing to enter more countries. We are addressing shortage situations and working with governments to supply medicines most in demand. We also have a strong manufacturing presence in Europe which can supply all our markets with sterile injectable products.

## Pursuing a holistic approach to meeting patient needs

We continue to grow and develop areas of our business that enable better patient outcomes and strengthen healthcare ecosystems.

### Expanding biosimilar treatment options in MENA

We leverage our strategic partnerships as well as our manufacturing and R&D expertise to expand biosimilar treatment options in MENA.

Through these partnerships, we are introducing new treatment options for chronic conditions and NCDs, improving access and affordability for patients and payers. This strategy is expanding the emerging biosimilars market and reducing the financial burden on healthcare systems in the region.

### Supporting HCPs to improve patient treatment and outcomes

The introduction of our sterile compounding business in the US enables HCPs to provide more personalised treatment options that better address individual patient needs. Diversifying our injectable business in the US to include 503B sterile compounding enables us to strengthen access to medicine through multiple means. Compounded sterile preparations are held to higher quality and safety standards and provide longer beyond-use dates than conventional medications. Sterile compounding also facilitates product availability and impacts drug shortage situations; as manufacturers can produce compounded sterile preparations in ready-to-use formats more quickly and cost effectively to supply to HCPs.

We continue to expand our portfolio to enable doctors, nurses and other HCPs to provide better, more personalised treatments for patients. Our continued growth of injectable medicines offered in prefilled syringes aims to improve the speed, safety, ease and accuracy of patient care.

## Our ambitions going forward

We aim to continue integrating accessibility and health equity into our core business and strategy by prioritising the following:

- Further alignment of our portfolio with neglected or priority disease areas
- Maintain collaboration with stakeholders to alleviate barriers to access
- Continued investment in local manufacturing to maintain strength in cost, reliability of supply
- Working with policymakers, payers and other stakeholders to address healthcare coverage
- Working with HCPs and patients to improve healthcare awareness and education
- Development of metrics that track and articulate our progress on access to medicine
- Continuing to work within our local communities to support vulnerable segments